Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration

Graefes Arch Clin Exp Ophthalmol. 2026 Jan;264(1):81-89. doi: 10.1007/s00417-025-06979-3. Epub 2025 Oct 13.
No abstract available

Keywords: Aflibercept 8 mg; Anti-vascular endothelial growth factor therapy; Neovascular age-related macular degeneration; Switching.